Genomic Health Inc logo

GHDX - Genomic Health Inc Share Price

$63.44 0.0  0.0%

Last Trade - 07/11/19

Sector
Healthcare
Size
Mid Cap
Market Cap £1.86bn
Enterprise Value £1.64bn
Revenue £344.0m
Position in Universe th / 6431
Bullish
Bearish
Unlock GHDX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

GHDX Revenue Unlock GHDX Revenue

Net Income

GHDX Net Income Unlock GHDX Revenue

Normalised EPS

GHDX Normalised EPS Unlock GHDX Revenue

PE Ratio Range

GHDX PE Ratio Range Unlock GHDX Revenue

Dividend Yield Range

GHDX Dividend Yield Range Unlock GHDX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
GHDX EPS Forecasts Unlock GHDX Revenue
Profile Summary

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated August 22, 2000
Public Since September 29, 2005
No. of Shareholders: 37
No. of Employees: 829
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Global Select Market
Shares in Issue 37,587,598
Free Float (0.0%)
Eligible for
ISAs
SIPPs
GHDX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to GHDX
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.